Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CO-DEVELOPMENT AGREEMENTCo-Development Agreement • February 26th, 2021 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Co-Development Agreement (“Agreement”), made effective as of February ___, 2021 (the “Effective Date”), is by and between Nektar Therapeutics, a Delaware corporation (“Nektar”), and SFJ Pharmaceuticals XII, L.P. (“SFJ”), a Delaware limited partnership (each, a “Party” and collectively, the “Parties”).
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PURCHASE AND SALE AGREEMENT dated as of December 16, 2020 between NEKTAR...Purchase and Sale Agreement • February 26th, 2021 • Nektar Therapeutics • Pharmaceutical preparations • New York
